News headlines about VBI Vaccines (NASDAQ:VBIV) have been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. VBI Vaccines earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.3736823304948 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:

VBI Vaccines (NASDAQ VBIV) traded down $0.07 during trading hours on Monday, hitting $4.13. The stock had a trading volume of 266,855 shares, compared to its average volume of 223,453. The company has a current ratio of 2.00, a quick ratio of 1.91 and a debt-to-equity ratio of 0.18. VBI Vaccines has a 52 week low of $2.78 and a 52 week high of $6.60.

Several equities analysts recently weighed in on the stock. Zacks Investment Research raised shares of VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Wednesday, August 23rd. Canaccord Genuity started coverage on VBI Vaccines in a report on Wednesday, November 1st. They set a “buy” rating and a $10.00 target price for the company. ValuEngine downgraded VBI Vaccines from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Finally, Noble Financial reaffirmed a “buy” rating on shares of VBI Vaccines in a research note on Monday, July 31st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. VBI Vaccines currently has a consensus rating of “Hold” and an average target price of $10.00.

TRADEMARK VIOLATION WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at

In related news, major shareholder Life Sciences Maste Perceptive purchased 3,100,000 shares of the stock in a transaction that occurred on Thursday, October 26th. The stock was acquired at an average cost of $3.05 per share, with a total value of $9,455,000.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Opko Health, Inc. purchased 655,738 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was bought at an average cost of $3.05 per share, with a total value of $2,000,000.90. The disclosure for this purchase can be found here. Insiders have bought 4,078,738 shares of company stock worth $12,444,511 over the last ninety days. 34.10% of the stock is owned by insiders.

VBI Vaccines Company Profile

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Insider Buying and Selling by Quarter for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.